...Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve... ...the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen... ...certificate of dissolution. NASDAQ also suspended trading of the stock on Aug. 29 and advised Maxygen...
...three-month operating loss of $2.2 million. Maxygen had a 2012 operating gain of $20.3 million. Maxygen's... ...company said it has no plans to independently continue development of MAXY-G34 for either indication. Maxygen Inc....
...small molecule kinase-targeted drug discovery for cancer. Perseid was formed under a 2009 JV with Maxygen Inc.... ...Genentech Inc. , South San Francisco, Calif. High Energy Accelerator Research Organization , Tsukuba, Japan Maxygen Inc.... ...OSI Pharmaceuticals Inc. and the remaining stake in Perseid Therapeutics LLC, a JV with Maxygen Inc....
Maxygen Inc., Santa Clara, Calif. Business: Enabling technology Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president and scientific...
...from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's... ...of recombinant Factor VIIa product (formerly MAXY-VII) and after undisclosed patent related conditions were met. Maxygen... ...is not eligible for any further payments under the deal (see BioCentury, July 7, 2008). Maxygen Inc....
...and €15.2 million ($19.5 million) in a private placement of 6.6 million shares at €2.30. Maxygen Inc.... ...milestone payment from Bayer AG (Xetra:BAYN) under a 2008 deal in which the pharma acquired Maxygen's...
...and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen... ...overseas manufacturing, uncertain IP issues for MAXY-G34 and the company's reliance on consultants and subcontractors. Maxygen... ...that cover mutated G-CSF molecules, which Maxygen said may cover MAXY-G34 (see BioCentury, Oct. 17). Maxygen Inc....
...Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve... ...the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen... ...certificate of dissolution. NASDAQ also suspended trading of the stock on Aug. 29 and advised Maxygen...
...three-month operating loss of $2.2 million. Maxygen had a 2012 operating gain of $20.3 million. Maxygen's... ...company said it has no plans to independently continue development of MAXY-G34 for either indication. Maxygen Inc....
...small molecule kinase-targeted drug discovery for cancer. Perseid was formed under a 2009 JV with Maxygen Inc.... ...Genentech Inc. , South San Francisco, Calif. High Energy Accelerator Research Organization , Tsukuba, Japan Maxygen Inc.... ...OSI Pharmaceuticals Inc. and the remaining stake in Perseid Therapeutics LLC, a JV with Maxygen Inc....
Maxygen Inc., Santa Clara, Calif. Business: Enabling technology Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president and scientific...
...from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's... ...of recombinant Factor VIIa product (formerly MAXY-VII) and after undisclosed patent related conditions were met. Maxygen... ...is not eligible for any further payments under the deal (see BioCentury, July 7, 2008). Maxygen Inc....
...and €15.2 million ($19.5 million) in a private placement of 6.6 million shares at €2.30. Maxygen Inc.... ...milestone payment from Bayer AG (Xetra:BAYN) under a 2008 deal in which the pharma acquired Maxygen's...
...and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen... ...overseas manufacturing, uncertain IP issues for MAXY-G34 and the company's reliance on consultants and subcontractors. Maxygen... ...that cover mutated G-CSF molecules, which Maxygen said may cover MAXY-G34 (see BioCentury, Oct. 17). Maxygen Inc....